Oncology trends: smaller indications and greater efficiency, says QuintilesIMS Institute

By Melissa Fassbender contact

- Last updated on GMT

The late-stage oncology pipeline has 631 unique molecules in development, according to the QuintilesIMS Institute. (Image: iStock/Bogdanhoda)
The late-stage oncology pipeline has 631 unique molecules in development, according to the QuintilesIMS Institute. (Image: iStock/Bogdanhoda)

Related tags: Clinical trial

As pharma targets smaller indications and becomes more efficient, oncology clinical trial duration – and patient enrollment – have decreased.

The number of patients enrolled in Phase III clinical trials declined from a high of 671 in 1998 to 188 patients in 2016, according to a report published by the QuintilesIMS Institute.

Additionally, trial duration declined from 2,000 days in 1997 to 1,070 in 2016.

As Michael Kleinrock, research director of the QuintilesIMS Institute explained, these numbers could indicate two things: that companies are targeting smaller indications and/or that companies are becoming more efficient at completing trials and thus, are doing so at a reduced cost.

Both are good things for those companies and for patients who get drugs sooner​,” he told Outsourcing-Pharma.com.

Trial designs that shift to having fewer measured end-points are ultimately simpler to complete faster​,” Kleinrock added. “Smaller indications may ultimately be rarer cancers, but since most of the large tumors have effective treatments, this is only natural​.”

The report also notes that clinical trial sponsors are employing improved trial design technologies​ to accelerate drug development. This includes the use of predictive biomarkers to target sub-populations within cancer types.

Those that are in R&D have been facing ever greater pressures to optimize R&D for time and cost and to get to market faster and at lower development cost​,” Kleinrock said.

As Outsourcing-Pharma.com previously reported​, biomarker-enabled drug programs are three times more likely to reach approval.

Ultimately, Kleinrock explained the key finding was that there are more, better cancer drugs on the market than ever before – and more are coming.

Related news

Show more

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars